MarketCap
Facebook
X
Telegram
Immunome Market Cap | IMNM
As of October 06, 2026 Immunome has a market cap of $ 1.85 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Immunome
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 B | 1.27 B | 490 M | 62.3 M | 150 M | 146 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | 62.3 M | 667 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
311 M | - | - | $ 24.9 M |  USA |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
2 B | - | - | - | Russia |
 |
Ionis Pharmaceuticals
IONS
|
12.9 B | $ 43.5 | 0.62 % | $ 6.96 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
356 M | $ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
160 M | $ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
490 M | $ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
2.01 B | $ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
2.99 B | $ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
400 B | $ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
252 M | $ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
3.65 B | $ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
126 M | $ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
287 M | $ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
224 M | $ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
139 M | $ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
97.8 M | $ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
1.13 M | $ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 0.91 | 5.26 % | $ 234 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
327 M | $ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
247 M | $ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
5.13 B | $ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
545 M | $ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
318 M | $ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
114 M | $ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
198 B | $ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
5.8 B | $ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
4.31 B | $ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
1.59 B | $ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
214 M | $ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
769 M | $ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
51.8 M | $ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
4.97 M | $ 0.68 | 0.16 % | $ 4.45 M | USA |